AirSculpt Technologies Q2 Earnings Call Highlights

2 weeks ago 8

MarketBeat

Mon, August 10, 2026 astatine 9:04 AM CDT 6 min read

Key Points

Interested successful AirSculpt Technologies, Inc.? Here are 5 stocks we similar better.
Q2 gross fell 2.5% to $42.9 million, portion same-center cases grew 1% twelvemonth implicit twelvemonth but were offset by a 2% diminution successful mean selling price. Adjusted EBITDA decreased to $4.9 cardinal arsenic the institution accrued selling spending.
AirSculpt is expanding beyond halfway fat-removal procedures to seizure request from GLP-1 users, adding tegument excision, bosom procedures and the planned rollout of alloClae. Management estimates expanded services could make much than $100 cardinal successful semipermanent gross crossed its existing centers.
The institution raised astir $5 cardinal successful equity during the 4th and ended with astir $24 cardinal successful liquidity, portion reducing debt. AirSculpt reaffirmed its gross outlook, lowered its 2026 adjusted EBITDA people to $12 million-$14 million owed to further selling investment, and expects comparable gross to diminution successful Q3 earlier improving successful Q4.

AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter gross of $42.9 million, down 2.5% from the prior-year period, arsenic the institution cited unchangeable gross trends, affirmative same-center lawsuit maturation and continued concern successful selling and expanded process offerings.

Chief Executive Officer Yogi Jashnani said the company's translation efforts person contributed to improving income comparisons. Same-center income improved by 21 percent points from the 2nd 4th of 2025 and by 23 percent points twelvemonth to date, helium said. On a comparable basis, the institution recorded astir level same-center income maturation successful the archetypal fractional of 2026.

→ Why the Landlord of the AI Boom Could Outlast the Chipmakers

"Our near-term absorption remains squarely connected expanding same-center sales," Jashnani said, portion adding that the institution sees longer-term maturation opportunities successful caller procedures and aboriginal de novo halfway enlargement arsenic its equilibrium expanse and currency procreation improve.

Case Growth Offset by Lower Selling Price

Chief Financial Officer Michael Arthur said second-quarter same-center revenue, excluding the interaction of the London location, declined astir 1% from a twelvemonth earlier. That effect reflected 1% same-center lawsuit growth, the company's 2nd consecutive 4th of year-over-year lawsuit growth, offset by a 2% diminution successful mean selling price.

→ MarketBeat Week successful Review – 08/03 - 08/07

Average selling terms was astir $12,700 during the quarter, which Arthur said remained wrong the company's humanities range. He attributed the year-over-year diminution principally to examination with an unusually precocious mean selling terms successful the prior-year quarter.

Read Entire Article